natgillin/translations-raw huggingface dataset:
Den gennemsnitlige procentdel af methylnaltrexonbromiddoser, der resulterede i enhver afføring uden behovsmedicin inden for 4 timer, var henholdsvis 28,9 % og 30,2 % for dosering én gang daglig og hver anden dag sammenlignet med 9,4 % og 9,3 % for det tilsvarende placeboregime (p <0,001).
The mean percentage of methylnaltrexone bromide resulting in any RFBM within 4 hours were 28.9% and 30.2% respectively for the once daily and every other day dose groups compared with 9.4% and 9.3% respectively for the corresponding placebo regimen (p < 0.001).
Den gennemsnitlige procentdel af methylnaltrexonbromiddoser, der resulterede i enhver afføring uden behovsmedicin inden for 4 timer, var henholdsvis 28,9 % og 30,2 % for dosering én gang daglig og hver anden dag sammenlignet med 9,4 % og 9,3 % for det tilsvarende placeboregime (p <0,001).
The mean percentage of methylnaltrexone bromide resulting in any RFBM within 4 hours were 28.9% and 30.2% respectively for the once daily and every other day dose groups compared with 9.4% and 9.3% respectively for the corresponding placebo regimen for daily and every other day dosing (p <0.001) during the double blind phase.
Den gennemsnitlige PUA ved baseline var 0,58 mmol/l (9,8 mg/dl).
The mean PUA at baseline was 9.8 mg/dl.
Den gennemsnitlige renale clearance af alogliptin (170 ml/min) var højere end den gennemsnitlige anslåede glomerulære filtrationshastighed (ca.
The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx.
Den gennemsnitlige samlede stimulationsvarighed var 9 dage for begge grupper, hvilket tydede på, at der var behov for to dage med recFSH for at gennemføre ovariestimulation fra stimulationsdag 8 og videre frem (recFSH blev givet på dagen med hCG-injektion i dette studie).
The median total duration of stimulation was 9 days for both groups, indicating that two days of recFSH were required to complete ovarian stimulation from stimulation day 8 onwards (recFSH was given on the day of hCG for this study).
Den gennemsnitlige serum-halveringstid (t½) for filgrastim lå i området mellem 2,7 timer (1,0 mill.
The median serum elimination half-life (t1/2) of filgrastim after single subcutaneous doses ranged from
Den gennemsnitlige steady state hæmning af trombocytaggregering var henholdsvis 74 % og 69 % for 5µM og 20 µM ADP og blev nået efter 3 til 5 dages administration af en vedligeholdelsesdosis på 10 mg prasugrel med en forudgående loading-dosis på 60 mg.
Mean steady-state inhibition of platelet aggregation was 74% and 69% respectively for 5 µM ADP and 20 µM ADP, and was achieved following 3 to 5 days of administration of the 10 mg prasugrel maintenance dose preceded by a 60 mg loading dose.
Den gennemsnitlige steady-state-dalkoncentration af golimumab i serum hos patienter med nr-aksial SpA var den samme som den, der blev observeret hos patienter med AS efter subkutan administration af 50 mg golimumab hver 4. uge.
Steady-state trough mean serum golimumab concentrations in patients with nr-Axial SpA were similar to those observed in patients with AS following subcutaneous administration of 50 mg golimumab every 4 weeks.
Den gennemsnitlige stigning i forhold til baseline i CD4+ tal var 146 x 106 celler/l hos patienter, der fik rilpivirin 25 mg, og 160 x 106 celler/l hos patienter, der fik efavirenz.
The mean increase from baseline in CD4+ counts was 146 x 106 cells/l in patients receiving rilpivirine 25 mg and 160 x 106 cells/l in patients receiving efavirenz.
Den gennemsnitlige stigning i forhold til baseline i CD4+-celletal var 230 celler/mm3 hos patienter behandlet med E/C/F/TAF og 211 celler/mm3 hos patienter behandlet med E/C/F/TDF (p = 0,024) ved uge 48.
The mean increase from baseline in CD4+ cell count was 230 cells/mm3 in E/C/F/TAF-treated patients and 211 cells/mm3 in E/C/F/TDF-treated patients (p = 0.024) at Week 48.
Den gennemsnitlige systemiske clearance af lamivudin er omkring 0,32 l/time/kg; overvejende ved renal clearance (> 70 %) via organisk kation transportsystemet.
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance (> 70 %) via the organic cationic transport system.
Den gennemsnitlige systemiske clearance af lamivudin er omkring 0,32 l/time/kg; overvejende ved renal clearance ( 70 %) via organisk kation transportsystemet.
The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, with predominantly renal clearance (>70%) via the organic cationic transport system.
Den gennemsnitlige T-score ved baseline for rygradens og lårbenshalsens knogle- mineraltæthed var henholdsvis -2,2 og -2,1.
Baseline spinal and femoral neck bone mineral density mean T-scores were -2.2 and -2.1, respectively.
Den gennemsnitlige terminale eksponentielle halveringstid for lenvatinib er omkring 28 timer.
The mean terminal exponential half- life of lenvatinib is approximately 28 hours.
Den gennemsnitlige terminale halveringstid for elimination varierede fra 15 til 16 dage for doseringsgruppen 2 x 500 mg og fra 17 til 21 dage for doseringsgruppen 2 x 1.000 mg.
Mean terminal elimination half-life ranged from 15 to 16 days for the 2 x 500 mg dose group and 17 to 21 days for the 2  1000 mg dose group.
Den gennemsnitlige terminale halveringstid for vardenafil hos patienter, der fik vardenafil 10 mg smeltetabletter, var mellem 4-6 timer.
The mean terminal half-life of vardenafil in patients receiving vardenafil 10 mg orodispersible tablets ranged between 4 – 6 hours.
Den gennemsnitlige terminale halveringstid for vardenafil hos patienter, der fik Vivanza 10 mg smeltetabletter, var mellem 4-6 timer.
The mean terminal half-life of vardenafil in patients receiving Vivanza 10 mg orodispersible tablets ranged between 4 – 6 hours.
Den gennemsnitlige tid til komplet afvænning fra iNO var 3,7 dage (95% CLs 1,17; 6,95) med bosentan og 2,9 dage (95% Confidence Limits (CLs) 1,26; 4,23) med placebo (p = 0,34).
The median time to complete weaning from iNO was 3.7 days (95% CLs 1.17, 6.95) on bosentan and 2.9 days (95% CLs 1.26, 4.23) on placebo (p = 0.34).
Den gennemsnitlige tid til komplet afvænning fra mekanisk ventilation var 10,8 dage (95% CLs 3,21; 12,21 dage) med bosentan og 8,6 dage (95% CLs 3,71; 9,66) med placebo (p = 0,24).
The median time to complete weaning from mechanical ventilation was 10.8 days (95% CLs 3.21, 12.21 days) on bosentan and 8.6 days (95% CLs 3.71, 9.66 days) on placebo (p = 0.24).
Den gennemsnitlige tid til maksimumkoncentration var 1 time, og den gennemsnitlige maksimumkoncentration var 195 µg/ml.
The mean time to peak concentration was 1 hour and the mean peak concentration 195 μg/ml.
Den gennemsnitlige tid, inden patienterne døde eller sygdomen blev forværret, var 15 måneder med Ibrutinib sammenlignet med 6 måneder med temsirolimus.
The average length of time before patients died or the disease got worse was 15 months with Ibrutinib versus 6 months with temsirolimus.
Den gennemsnitlige tilsyneladende clearance (CL/F) af enzalutamid hos patienter er fra 0,520 til 0,564 l/h.
The mean apparent clearance (CL/F) of enzalutamide in patients ranges from 0.520 and 0.564 L/h.
Den gennemsnitlige tilsyneladende clearance af 0,75 mg og 1,5 mg dulaglutid ved steady state var 0,111 l/t og 0,107 l/t med en eliminationshalveringstid på hhv.
The mean apparent clearance of dulaglutide 0.75 mg and 1.5 mg at steady state was 0.111 L/h and
Den gennemsnitlige tilsyneladende clearance af ubundet perampanel hos personer med let nedsat leverfunktion var 188 ml/min vs.
The mean apparent clearance of unbound perampanel in mildly impaired subjects was 188 ml/min vs.
Den gennemsnitlige tilsyneladende halveringstid var 75,0 timer (interval fra 36,1 - 125 timer).
The mean apparent half-life was 75.0 hours (range 36.1–125 hours).
Den gennemsnitlige totale clearance var 102 og 112 l/t. efter første dosis på henholdsvis 1,0 mg/m2 og
Mean total body clearances were 102 and 112 l/h following the first dose for doses of 1.0 mg/m2 and
Den gennemsnitlige totale clearance var 102 og 112 l/t. efter første dosis på henholdsvis 1,0 mg/m2 og 1,3 mg/m2.
Mean total body clearances were 102 and 112 l/h following the first dose for doses of 1.0 mg/m2 and
Den gennemsnitlige trough serumkoncentration  SD før femte dosis var 7.6  4.0 g/ml.
The mean  standard deviation trough serum concentration prior to fifth dose was 7.6  4.0 g/ml.
Den gennemsnitlige udskillelse ved dialyse var i intervallet 16 – 32 ml/timer/kg High-flux dialysefiltret var mere effektivt sammenlignet med low-flux-filtret.
The mean dialysis clearance was between the range of 16-32 ml/h/kg.
Den gennemsnitlige ugentlige dosis er 15-20 mg.
The average weekly dose is 15-20 mg.
Den gennemsnitlige varighed af bosentan- og placebobehandlingen var henholdsvis 4,5 dage (interval 0,5-10,0 dage) og 4,0 dage (interval 2,5-6,5 dage).
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5–10.0 days) and 4.0 days (range 2.5-6.5 days).
Den gennemsnitlige varighed af bosentan- og placebobehandlingen var henholdsvis 4,5 dage (interval 0,5-10,0 dage) og 4,0 dage (interval 2,5-6,5 dage).
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5–10.0 days) and 4.0 days (range 2.5–6.5 days).
Den gennemsnitlige varighed af den længste episode var 18 dage i Perjeta-gruppen og 8 dage i placebo–gruppen.
The median duration of the longest episode was 18 days in Perjeta-treated patients and 8 days in placebo-treated patients.
Den gennemsnitlige varighed af indtagelse af eltrombopag var 171 dage.
The median duration of exposure was 171 days.
Den gennemsnitlige varighed af indtagelse af eltrombopag var 183 dage.
The median duration of exposure was 183 days.
Den gennemsnitlige varighed af indtagelse af eltrombopag var 260 dage.
The mean duration of exposure to eltrombopag was 260 days.
Den gennemsnitlige varighed af neutropeni- og trombocytopeniepisoderne varierede sædvanligvis fra henholdsvis 2–3 uger og 3–4 uger.
The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3 weeks, and from 3 to 4 weeks, respectively.
Den gennemsnitlige varighed af neutropeni- og trombocytopeniepisoderne varierede sædvanligvis fra henholdsvis 2–3 uger og 3–4 uger.
The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3weeks, and from 3 to 4weeks, respectively.
Den gennemsnitlige varighed for abatacept-behandlingen i periode C var 1.815 dage (med et spænd på 57-2.415 dage; næsten 61 måneder).
The median duration of abatacept treatment in Period C was 1815 days (range 57–2,415 days; nearly 61 months).
Den gennemsnitlige varighed for eksponering for bosentan var 1,9 år ± 0,7 år; (min: 0,1 år; max: 3,3 år) og patienterne blev observeret i gennemsnitligt 2,0 ± 0,6 år.
The mean duration of exposure to bosentan was 1.9 years  0.7 years (min: 0.1 years; max: 3.3 years) and patients were observed for a mean of 2.0  0.6 years.
Den gennemsnitlige vægtstigning i stabiliseringsfasen (op til 26 uger) med Aripiprazole var 3,2 kg, og en yderligere gennemsnitlig vægtstigning på 2,2 kg for Aripiprazole, sammenlignet med 0,6 kg for placebo, blev observeret i den anden fase (16 uger) af studiet.
The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial.
Den gennemsnitlige ± SD EC50 af sofosbuvir mod kimære replikoner, der koder NS5B-sekvenser fra kliniske isolater var 0,068 ± 0,024 μM for genotype 1a (n = 67),
The mean ± SD EC50 of sofosbuvir against chimeric replicons encoding NS5B sequences from clinical isolates was 0.068 ± 0.024 μM for genotype 1a (n = 67),
Den gennemsnitlige ændring fra baseline for hiv 1-rna og CD4-tal i uge 48 af behandlingen var næsten ens i begge behandlingsgrupper (-3,09 og -3,09 log10 kopier/ml; +169 og 167 celler/mm3 i henholdsvis 245 mg tenofovirdisoproxil (som fumarat) og stavudin gruppen).
The average change from baseline for HIV-1 RNA and CD4 count at 48 weeks of treatment was similar in both treatment groups (-3.09 and -3.09 log10 copies/ml; +169 and 167 cells/mm3 in the tenofovir disoproxil 245 mg (as fumarate) and stavudine groups, respectively).
Den gennemsnitlige ændring fra baseline i blodtryk (i siddende stilling) var størst efter 1 time, -9,1 mmHg (SD ± 12,5) og
The mean changes from baseline in sitting blood pressure were greatest at 1 hour,
Den gennemsnitlige ændring fra baseline i den 100-points OSDI-score var-13,6 med IKERVIS og - 14,1 med kontrollen ved måned 6 (p=0,858).
The mean change from baseline in the 100-point OSDI score was -13.6 with IKERVIS and -14.1 with vehicle at Month 6 (p=0.858).
Den gennemsnitlige ændring fra baseline i ubehag i øjnene (vurderet vha. en visuel, analog skala) var - 12,82 med IKERVIS og -11,21 med kontrollen (p=0,808).
The mean change from baseline in ocular discomfort score (assessed using a Visual Analogic Scale) was -12.82 with IKERVIS and -11.21 with vehicle (p=0.808).
Den gennemsnitlige ændring fra baseline til og med uge 24 i FEV1 (l) var 0,37 l i ivacaftor- gruppen og 0,01 l i placebo-gruppen i studie 1, og 0,30 l i ivacaftor-gruppen og 0,07 l i placebogruppen i studie 2.
The mean change from baseline through week 24 in FEV1 (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2.
Den gennemsnitlige ændring fra baseline til uge 12 (sidste observation indtil uge 12) i CHEST-2 (28 uger i studiet for CHEST-1 + CHEST-2) var 63 m i gruppen, der tidligere fik 1,0-2,5 mg riociguat, og 35 m i gruppen, der tidligere fik placebo.
The mean change from baseline to week 12 (last observation until week 12) in CHEST-2 (28 weeks on-study for CHEST-1 + CHEST-2) was 63 m in the former 1.0–2.5 mg riociguat group and 35 m in the former placebo group.
Den gennemsnitlige ændring fra baseline til uge 12 (sidste observation indtil uge 12) i PATENT-2 (24 uger i studiet for PATENT-1 + PATENT-2) var 53 m i gruppen, der tidligere fik 1,0-2,5 mg riociguat, 42 m i gruppen, der tidligere fik placebo, og 54 m i gruppen, der tidligere fik 1,0-1,5 mg riociguat.
The mean change from baseline to week 12 (last observation until week 12) in PATENT-2 (24 weeks on-study for PATENT-1 + PATENT-2) was 53 m in the former 1.0–2.5 mg riociguat group, 42 m in the former placebo group and 54 m in the former 1.0–1.5 mg riociguat group.
Den gennemsnitlige ændring i AAUCMB (Log10 kopier/ml) i ITT(E) populationen (observeret analyse) ved uge 48 (det primære endepunkt) og andre effektresultater opdelt i undergrupper er beskrevet i tabellerne nedenfor:
The mean AAUCMBs (log10 c/ml) in the ITT (E) population (Observed analysis) at 48 weeks (primary end-point) and other efficacy outcomes by subgroup are described in the tables below:
Den gennemsnitlige ændring i fasteplasmaglucose fra baseline til uge 52 ved administration af 25 mg alogliptin plus 30 mg pioglitazon plus metformin var desuden signifikant større end den gennemsnitlige ændring, der blev registreret ved administration af 45 mg pioglitazon plus metformin (p < 0,001).
In addition, mean change from baseline in FPG at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p<0.001).
Den gennemsnitlige ændring i parenteralt ernæringsvolumen fra baseline til uge 12 hos ITT- populationen, baseret på data fra lægeordinationer, var -2,57 (±3,56) l/uge svarende til et gennemsnitligt fald på -39,11 % (±40,79) sammenlignet med 0,43 (±0,75) l/uge svarende til en stigning på 7,38 % (±12,76) i kohorten med standardbehandling.
The mean change in parenteral nutrition volume from baseline at Week 12 in the ITT population, based on physician-prescribed data, was -2.57 (±3.56) l/week, correlating to a -39.11% (±40.79) mean decrease, compared to 0.43 (±0.75) l/week, correlating to a 7.38% (±12.76) increase in the standard of care cohort.
Den gennemsnitlige øgning af olanzapin AUC var henholdsvis 52 % og 108
The mean increase in olanzapine AUC was 52 % and 108 % respectively.
Den gennemsnitlige øgning af olanzapin Cmax efter fluvoxamin var 54 % hos kvindelige ikke-rygere og 77 % hos mandlige rygere.
The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female non- smokers and 77 % in male smokers.
Den gennemsnitlige øgning af olanzapin Cmax efter fluvoxamin var 54 % hos kvindelige ikke-rygere og 77 % hos mandlige rygere.
The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female non- smokers and 77 % male smokers.
Den gennemsnitlige øgning af olanzapin Cmax efter fluvoxamin var 54 % hos kvindelige ikke-rygere og 77 % hos mandlige rygere.
The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non- smokers and 77% in male smokers.
Den gennemsnitlige ’residence’ tid er cirka 5 timer.
The mean residence time is approximately 5 hours.
Den gennemsnitlige, absolutte biotilgængelighed efter en enkelt, sublingual administration af Zalviso i forhold til én et-minuts intravenøs infusion af 15 mikrogram sufentanil var 59 %.
Mean absolute bioavailability after a single sublingual administration of Zalviso relative to a one- minute intravenous sufentanil infusion of 15 micrograms was 59 %.
Den geometriske gennemsnitlige eksponering for nintedanib var 33 % højere hos kinesiske, taiwanesiske og indiske patienter, mens den var 22 % lavere hos koreanere, sammenlignet med kaukasiere (korrigeret for legemsvægt).
The geometric mean exposure to nintedanib was 33% higher in Chinese, Taiwanese, and Indian patients while it was 22% lower in Koreans compared to Caucasians (body weight corrected).
Den geometriske gennemsnitlige eksponering for nintedanib var 33 % større hos kinesiske, taiwanesiske og indiske patienter, mens den var 22 % lavere hos koreanere, sammenlignet med kaukasiere (korrigeret for legemsvægt).
The geometric mean exposure to nintedanib was 33 % higher in Chinese, Taiwanese, and Indian patients while it was 22 % lower in Koreans compared to Caucasians (body weight corrected).
Den geometriske gennemsnitsratio AUClast var 0,99, og 90% konfidensintervaller var 80,18%-122,80%.
The AUClast- geometric mean ratio was 0.99 and 90% confidence intervals were 80.18%- 122.80%.
Den geometriske gennemsnitsratio AUClast var 0,99, og 90-%-konfidensintervaller var 80,18 %- 122,80 %.
The AUClast geometric mean ratio was 0.99 and 90% confidence intervals were 80.18%-122.80%.
Den geometriske gennemsnitsratio og 90 % konfidensintervallet for de primære farmakokinetiske endepunkter var 1,01 [90 % konfidensinterval 0,959-1,07] og 1,02 [90 % konfidensinterval 0,956- 1,10] for henholdsvis AUC0-21 dage og Cmax.
The geometric mean ratio and 90% CI for the primary PK endpoints were 1.01 [90%CI: 0.959-1.07] and 1.02 [90%CI: 0.956-1.10] for AUC0-21 days and Cmax, respectively.
Den geometriske middel- antistofkoncentration af anti-HB var lavere ved samtidig administration, men den kliniske betydning af denne observation kendes ikke, idet seroprotektionsraten forbliver den samme.
Anti- HBs geometric mean antibody concentrations were lower on co-administration, but the clinical significance of this observation is not known since the seroprotection rates remain unaffected.
Den geometriste middelværdi ratio for Viramune i depotform i forhold til Viramune 200 mg var ~90 % for Cmin,ss og for AUCss med 90 % konfidensintervaller inden for 80 %-125 %; ratio for Cmax,ss var lavere og konsistent med én gang dagligt depotdoseringsform.
The observed geometric mean ratios of Viramune prolonged-release to Viramune immediate-release were ~90 % for Cmin,ss and AUCss with 90 % confidence intervals within 80 %-125 %; the ratio for Cmax,ss was lower and consistent with a once-daily prolonged-release dosage form.
Den gives som beskyttelse mod sygdomme forårsaget af Human papillomavirus HPV-type 6, 11, 16, 18, 31, 33, 45, 52 og 58.
It is given to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
Den gives som et drop (infusion) i en vene i løbet af 1-2 timer, men infusionen kan vare længere, hvis der optræder bivirkninger som rødmen og svimmelhed.
It is given as a drip (infusion) into a vein over 1- 2 hours, but the infusion may last longer if side effects like flushing and dizziness occur.
Den gives til Dem i en blodåre af en læge eller sygeplejerske.
It will be administered into a vein by a health care professional.
Den gives ved injektion i overarmsmusk- len.
It is given by injection into the upper arm muscle.
Den gives ved injektion i overarmsmusklen eller låret.
It is given by injection into the upper arm muscle or the thigh.
Den givne dosis skal reduceres med 50 % i tilfælde af forekomst af hæmatologiske lidelser (hvide blodlegemer < 1.500/mm3, granulocytter < 1.000/mm3, thrombocytter < 100.000/mm3).
The administered dose should be reduced by 50 % in case of occurrence of haematological disorders (white blood cells < 1,500/mm3, granulocytes < 1,000/mm3, thrombocytes < 100,000/mm3).
Den godkendte opbevaringstid for EVICEL er 24 måneder ved temperaturer ≤ -18 ºC.
The approved shelf life of EVICEL is 24 months storage at ≤ -18oC.
Den godkendte opbevaringstid for EVICEL er 24 måneder ved temperaturer ≤ -18oC.
The approved shelf life of EVICEL is 24 months storage at ≤ -18oC.
Den graduerede fyldte injektionssprøjte gør det muligt at give doser fra 20 til 100 mg.
The graduated pre-filled syringe allows for doses between 20 and 100 mg.
Den grå kanylehætte mangler eller ikke er sat ordentlig på.
The grey needle cap is missing or not securely attached.
Den grå kanylehætte mangler eller ikke er sat ordentligt på.
The grey needle cap is missing or not securely attached.
Den grå kanylehætte på den fyldte injektionssprøjte med Repatha består af tørt naturgummi, der er fremstillet af latex.
The grey needle cap on the Repatha pre-filled syringe is composed of dry natural rubber, which is made from latex.
Den grønne 10 mikrogram Lyxumia-pen er tom, når det sorte stempel har nået ”0” på dosisskalaen, og injektionsknappen ikke kan trækkes helt ud.
The green 10 microgram Lyxumia pen is empty when the black plunger has reached ‘0’ on the dose scale and the injection button cannot be pulled out fully.
Den grønne indikator viser, hvor langt indsprøjtningen er nået.
The green indicator shows the progress of the injection.
Den grønne pen indeholder 14 forudindstillede doser; hver dosis indeholder 10 mikrogram Lyxumia.
The green pen contains 14 pre-set doses; each dose contains 10 micrograms of Lyxumia.
Den grønne stempelstang skal kunne ses gennem sprøjtecylinderen.
The green plunger rod should show through the body of the syringe.
Den grønne tredobbelte pakning nr.
Use green triple pack No.
Den gule indikator er forbundet med stemplet i den fyldte pen.
The yellow indicator is connected to the plunger of the pre-filled pen.
Den gule indikator vil fylde omkring halvdelen af vinduet.
The yellow indicator will fill about half of the viewing window.
Den gule tredobbelte pakning nr.
Use yellow triple pack No.
Den gunstige responsfordeling, i henhold til indikation, var ved afslutningen af caspofunginbehandlingen følgende i MITT-analysen: 81% (30/37) ved invasiv candidiasis, 50% (5/10) ved invasis aspergillosis og 100% (1/1) ved candidiasis i øsofagus.
The favorable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81 % (30/37) in invasive candidiasis, 50 % (5/10) in invasive aspergillosis, and 100 % (1/1) in esophageal candidiasis.
Den har en mørkeblå dosisknap med en forhøjet ring.
It has a dark blue injection button with a raised ring on the top.
Den har en mørkeblå dosisknap med en ophøjet ring Efter fjernelse af penhætten skal insulinets udseende også kontrolleres: insulinopløsningen skal være klar, farveløs, uden synlige faste partikler og skal have en vandlignende konsistens.
After removing the pen cap, the appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.